Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

期刊论文
发表日期：

2024年6月25日

查看全文

F. Poumeaud,
M. Morisseau,
L. Cabel,
A. Gonçalves,
C. Rivier,
O. Trédan,
E. Volant,
J.-S. Frenel,
S. Ladoire,
W. Jacot,
M. Jamelot,
H. Foka Tichoue,
A. Patsouris,
L. Teixeira,
F.-C. Bidard,
D. Loirat,
M. Brunet,
C. Levy,
C. Bailleux,
B. Cabarrou,
A. Deleuze,
L. Uwer,
E. Deluche,
T. Grellety,
C. Franchet,
F. Fiteni,
H. Bischoff,
R. Vion,
M. Pagliuca,
B. Verret,
S. Bécourt,
T. Reverdy,
A. de Nonneville,
F. Dalenc

摘要

Background

Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.

Methods

ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC.

Results

One hundred and seventy-nine patients were included: the majority with HR-negative tumours received SG first (ADC1) (n = 100/108) while most with HR-positive tumours received T-DXd first (n = 56/71). Median progression-free survival 2 was short: 2.7 months (95% CI: 2.4–3.3) in the whole population, respectively, 3.1 (95% CI: 2.6–3.6) and 2.2 months (95% CI: 1.9–2.7) for patients receiving T-DXd or SG second (ADC2). Intermediary lines of chemotherapy between ADC1 and ADC2 had no impact. Primary resistance to ADC2 occurred in 54.4% of patients. Certain patients showed initial response to ADC2.

Conclusions

Clinical benefit of sequentially administered SG and T-DXd is limited for most patients. Nevertheless, a subset of patients might benefit—on the short term—from a second ADC. Additional studies are needed to identify patients who could benefit from two ADCs with similar payloads.